company background image
NLTX logo

Neoleukin Therapeutics NasdaqCM:NLTX Stock Report

Last Price

US$13.96

Market Cap

US$32.8m

7D

4.5%

1Y

59.5%

Updated

20 Dec, 2023

Data

Company Financials

Neoleukin Therapeutics, Inc.

NasdaqCM:NLTX Stock Report

Market Cap: US$32.8m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

NLTX Stock Overview

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. More details

NLTX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis

Earnings have declined by 4.3% per year over past 5 years

Makes less than USD$1m in revenue ($0)

Highly volatile share price over the past 3 months

Shareholders have been diluted in the past year


My Notes

Capture your thoughts, links and company narrative

Neoleukin Therapeutics, Inc. Competitors

ProMIS Neurosciences

NasdaqCM:PMN

US$29.1m

Lisata Therapeutics

NasdaqCM:LSTA

US$31.1m

RenovoRx

NasdaqCM:RNXT

US$36.0m

AgeX Therapeutics

NYSEAM:AGE

US$31.5m

Price History & Performance

Summary of share price highs, lows and changes for Neoleukin Therapeutics
Historical stock prices
Current Share PriceUS$13.96
52 Week HighUS$18.80
52 Week LowUS$8.11
Beta1.1
1 Month Change5.76%
3 Month Change-0.14%
1 Year Change59.51%
3 Year Change-93.52%
5 Year Change-66.44%
Change since IPO-94.16%

Recent News & Updates

Is Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Invest In Growth?

Jul 18
Is Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Invest In Growth?

Here's Why We're Watching Neoleukin Therapeutics' (NASDAQ:NLTX) Cash Burn Situation

Mar 10
Here's Why We're Watching Neoleukin Therapeutics' (NASDAQ:NLTX) Cash Burn Situation

Recent updates

Is Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Invest In Growth?

Jul 18
Is Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Invest In Growth?

Here's Why We're Watching Neoleukin Therapeutics' (NASDAQ:NLTX) Cash Burn Situation

Mar 10
Here's Why We're Watching Neoleukin Therapeutics' (NASDAQ:NLTX) Cash Burn Situation

We're Keeping An Eye On Neoleukin Therapeutics' (NASDAQ:NLTX) Cash Burn Rate

Nov 19
We're Keeping An Eye On Neoleukin Therapeutics' (NASDAQ:NLTX) Cash Burn Rate

Is Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Deliver On Growth Plans?

Jun 03
Is Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Deliver On Growth Plans?

Shareholder Returns

NLTXUS BiotechsUS Market
7D4.5%-0.2%3.2%
1Y59.5%-7.0%24.2%

Return vs Industry: NLTX exceeded the US Biotechs industry which returned 1.7% over the past year.

Return vs Market: NLTX exceeded the US Market which returned 22% over the past year.

Price Volatility

Is NLTX's price volatile compared to industry and market?
NLTX volatility
NLTX Average Weekly Movement7.7%
Biotechs Industry Average Movement11.2%
Market Average Movement6.5%
10% most volatile stocks in US Market18.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: NLTX's share price has been volatile over the past 3 months.

Volatility Over Time: NLTX's weekly volatility has increased from 44% to 87% over the past year.

About the Company

FoundedEmployeesCEOWebsite
20037Donna Cochener-Metcalfewww.neoleukin.com

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company’s lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019.

Neoleukin Therapeutics, Inc. Fundamentals Summary

How do Neoleukin Therapeutics's earnings and revenue compare to its market cap?
NLTX fundamental statistics
Market capUS$32.80m
Earnings (TTM)-US$34.26m
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.0x

P/E Ratio

Is NLTX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NLTX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$34.26m
Earnings-US$34.26m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-14.58
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did NLTX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/12/20 01:15
End of Day Share Price 2023/12/18 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Neoleukin Therapeutics, Inc. is covered by 14 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael UlzBaird
Gregory HarrisonBofA Global Research
Corey DavisCanaccord Genuity